RTP Mobile Logo
What Clinicians Want To Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes (Webinar Video Proceedings)
Released January 2022

Featuring perspectives from Drs Alice Mims, Alexander Perl, Richard Stone and Geoffrey Uy, moderated by Dr Harry Paul Erba. Published January 21, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia and myelodysplastic syndromes.


    • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
    • Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals appropriate for treatment with this novel agent.
    • Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
    • Develop an understanding of the mechanisms of action of, recent data with and current roles for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or IDH2 mutation.
    • Assess the FDA-approved indication for CPX-351 for patients with therapy-related or newly diagnosed AML with myelodysplasia-related changes, and discern how this agent can be safely and optimally integrated into nonresearch care algorithms.
    • Formulate a treatment algorithm for patients with lower- and higher-risk myelodysplastic syndromes (MDS), considering patient- and disease-related factors including cytogenetic abnormalities.
    • Develop an understanding of the biologic rationale for and available data with emerging novel combination approaches for individuals with higher-risk MDS to prepare for their potential availability in routine practice.
    • Recall promising agents and strategies under investigation for AML and MDS, and counsel appropriately selected patients regarding clinical trial enrollment.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 2.25 (Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASH2021/AMLMDS/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY AND MODERATOR — The following faculty reported relevant financial relationships with ineligible entities:

    Alice S Mims, MD, MSCR
    Acute Leukemia Clinical Research Director
    Associate Professor, Division of Hematology
    The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio

    Advisory Committee: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc, Kura Oncology, Syndax Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Aptevo Therapeutics, Astex Pharmaceuticals, Kartos Therapeutics, Karyopharm Therapeutics, Leukemia & Lymphoma Society, Plexxikon Inc, Xencor; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc, Jazz Pharmaceuticals Inc; Other: Leukemia & Lymphoma Society — Senior Medical Director for the Beat AML study.

    Alexander Perl, MD
    Associate Professor of Medicine
    Perelman School of Medicine
    Member, Leukemia Program
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Syndax Pharmaceuticals Inc;Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Sumitomo Dainippon Pharma Oncology Inc;Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc;Data and Safety Monitoring Board/Committee: Beat AML LLC, Leukemia & Lymphoma Society. 

    Richard M Stone, MD
    Professor of Medicine
    Harvard Medical School
    Chief of Staff
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Aprea Therapeutics, Arog Pharmaceuticals Inc, BerGenBio ASA, Boston Pharmaceuticals, Bristol-Myers Squibb Company, ElevateBio, Foghorn Therapeutics, GEMoaB, GlaxoSmithKline, Innate Pharma, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Novartis, Onconova Therapeutics Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc.

    Geoffrey L Uy, MD
    Professor of Medicine
    Division of Oncology
    Washington University School of Medicine
    St Louis, Missouri

    No relevant conflicts of interest to disclose.


    Harry Paul Erba, MD, PhD
    Director, Leukemia Program
    Instructor in the Department of Medicine
    Member of the Duke Cancer Institute
    Duke University School of Medicine
    Durham, North Carolina

    Advisory Committee and Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlycoMimetics Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Novartis, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, ALX Oncology, Amgen Inc, Daiichi Sankyo Inc, FORMA Therapeutics, Forty Seven Inc, Gilead Sciences Inc, GlycoMimetics Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, MacroGenics Inc, Novartis, PTC Therapeutics; Independent Review Committee: AbbVie Inc; Speakers Bureau: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Jazz Pharmaceuticals Inc and Servier Pharmaceuticals LLC.

    Release date: January 2022
    Expiration date: January 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):